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Michael Henry Bass: Effects of Transdermal Magnesium Chloride on Recovery of Force 
Production and Perceived Muscle Soreness after Eccentric Exercise                                             
(Under the Direction of Erik Hanson) 
 
Purpose: To examine the effects of transdermal magnesium chloride (tMgCl2) application 
on recovery in isometric force production and perceived muscle soreness following a bout of 
eccentric leg extensions. Methods: 19 recreationally active men completed a randomized, double 
blinded, crossover of isometric force production and muscle soreness assessment. Isometric knee 
extensor strength and perceived muscle soreness were assessed immediately following eccentric 
exercise intervention and at 24, 48, and 96 hours. Results: tMgCl2 did not reduce perceived muscle 
soreness (p=0.510) or increasing muscle force recover (p=0.742). However, there was a slightly 
attenuated degree of pain and 4% increase in force production after accounting for the effects of 
leg dominance. Conclusion: tMgCl2 may be beneficial for the micro-cycle phase of training. 
Future studies should consider investigating using higher dosages or longer supplementation 
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CHAPTER I: Introduction 
 
Athletic success is often decided by the slimmest of margins, with the slightest advantage 
in performance being the difference between victory and defeat. To maximize performance, 
athletes may elicit extraneous sources of aid, which can be in the form of supplementation. It is 
common for athletes to turn to supplementation and other ergogenic aids to help them reach their 
maximum potential during events (Knapik 2016). From 2013-2018, supplement sales in the U.S. 
have almost grown by 14 billion dollars and is projected to reach 52 billion dollars by the end of 
2019 (Statista).  There is a multitude of different vitamins, minerals, and other herbal products 
available that claim to boost baseline levels within the body or, to minimize or reverse potential 
deficiencies, and theoretically providing athletes with physiologically optimal conditions to 
perform and compete. Because supplements are unregulated and often lack scientific evidence to 
support such claims, data are necessary to support or refute purported benefits. While some 
nutritional supplements have evidence to support their effectiveness (Peeling et al., 2018), many 
products have nothing more than anecdotal evidence or manufacturer claims.  
Magnesium is of the most commonly reported deficiencies (Moshfegh et al. 2009) yet is 
necessary for more than 300 enzymatic process (Jahnen-Dechent 2012), including ATP production 
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and muscle force production during in the contraction cycle (Newhouse et al, 2000, Bohl et al, 
2002). Magnesium also plays a pivotal role in protein synthesis, proper muscle and nerve function, 
blood pressure and glucose maintenance (Institute of Medicine 1997, Rude RK 2010, Rude RK 
2012). This mineral is also necessary for different metabolic processes and the subsequent energy 
production, including oxidative phosphorylation and glycolysis. Magnesium is also a key factor in 
developing bone, genetic coding, and the maintaining of structure and function of the cellular 
membrane (Rude RK 2012). Proper functioning is imperative to adequate force output necessary 
for many athletic competitions, especially in those that require sustained high levels of lower body 
power output. The ability to maintain force production during high intensity efforts may help 
prevent fatigue and improve athletic performance.  
Serum magnesium levels and muscle performance have been shown to be positively 
correlated for outcomes like grip strength and vertical jump (Brilla et al 1992: Santos et al 2012). 
However, most studies examining the effects of magnesium on performance utilize oral 
magnesium supplementation or dietary intake (Zhang 2017). Oral magnesium supplementation 
has been shown to have a positive effect on magnesium levels within the body while enhancing 
some performance outcomes like grip strength, lower-leg muscle power, knee extension torque, 
and ankle extension strength (Dominguez 2006). However, this method of ingestion and absorption 
may not be the most effective. One of the caveats of oral intake is that the magnesium has to be 
absorbed through the intestinal track before moving into the blood stream (Sircus 2007). This 
method of entry also requires that the magnesium be carried throughout the blood stream to 
working muscles to be used at the cellular level. This is less than ideal during athletic performance. 
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The majority of dietary magnesium is absorbed through the small intestine, with approximately 
24–76% is absorbed in the gut and the rest is eliminated in the feces (Jahnen-Dechent 2012). This 
less than optimal absorption may be accompanied by some of the more common side effects of 
oral supplementation like nausea and mild diarrhea (Venturini 2015). Transdermal application may 
provide a more optimal delivery for use in sport, by circumventing the digestion track and avoiding 
the gastrointestinal absorption.  
Transdermal magnesium chloride (tMgCl2) is an alternative application method that may 
reduce some of the limitations seen with oral intake. Transdermal application provides a more 
direct localized approach by applying the supplemental magnesium as a topical agent and allowing 
the magnesium ions to diffuse through the epidermis layer (Sircus 2007, Chandrasekaran et al 
2016). As such, this application style directly targets the muscles after being absorbed through the 
epidermal layer without having to enter into circulation. There has been evidence of oral 
supplementation having a positive effect on performance, but the effectiveness of transdermal 
delivery showing the same result has yet to be shown, thus recommending this application method 
currently lacks support (Gröber 2017). 
Currently the use of tMgCl2 to aid muscle performance has not been thoroughly researched 
(Zhang 2017). There has only been one study, to our knowledge, investigating the utilization of 
tMgCl2 on muscle performance (Gulick 2012). This study found no differences between tMgCl2 
and placebo for cycling time to failure, but there was a difference over time in measuring ankle 
flexibility. While Gulick and colleagues did not detect any effects from tMgCl2, they used an acute 
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application protocol. The use of repeated tMgCl2 over multiple time points (chronic 
supplementation) allows for a more direct comparisons to the use of oral supplementation. 
Moreover, with the anti-inflammatory properties of magnesium in regards to cellular maintenance, 
it is possible that tMgCl2 may be suitable to examine during the on recovery process. With 
increased recovery from strenuous bouts of exercise, athletes may be able to train harder in terms 
of intensity and volume during the microcycle, thus allowing for greater adaptations during the 
macrocycle. These small adaptations throughout the training program may be the difference in 
victory and defeat.  
Purpose Statement 
 Purpose of this study was to examine the effects of tMgCl2 application on recovery in 
isometric force production and perceived muscle soreness following a bout of lower body 
eccentric leg extensions.  
Research Questions 
RQ1: Does tMgCl2 enhance recovery and subsequently increase isometric force production after 
a bout of eccentric leg extensions on an isokinetic dynamometer? 
RQ2: Does tMgCl2 decrease muscle soreness after a bout of eccentric leg extensions? 
Hypotheses  
1) There would be a significant interaction of  time and condition, and applying tMgCl2 
oil and balm three times daily following eccentric leg extensions will increase rates of 
recovery of isometric force production at 24, 48, and 96 hours compared to a placebo.   
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2) There would be a significant interaction of  time and condition, and application of tMgCl2 
oil and balm will decrease perceived muscle soreness following eccentric leg extensions 
compared to a placebo 
Operational Definitions  
 Familiarization: Session that occurred prior to the pre-testing session to introduce and prepare 
the participants to successfully complete the protocols and equipment being used in this study. 
 Isokinetic dynamometer: A device that resisted applied forces and controlled the speed of 
exercise at a predetermined rate. 
 Isometric force production: Muscular force measured from an isometric contraction  
Delimitations  
 All participants were males between the ages of 18 and 35 and were recreationally active 
(30 minutes of exercise at least 2 times per week) for at least 2 months prior to enrollment 
 All participants had previous experience (at least 2 months) with resistance exercises 
 Participants had no history of  knee injuries with surgery in the past year 
 Participants must not have previously had any known magnesium deficiency, magnesium 
supplementation therapy or multi-vitamin use 
 Participants were not taking chronic pain medication 
 All participants had no history of cardiovascular or respiratory conditions which could 




 The results of this study were only applicable to those who are men, recreationally active 
and between the ages of 18-35 years old. Results may not be applied to males of all ages 
and females 
 It is possible that subjects did not adhere to supplement application or exercise guidelines 
during the trail weeks as researchers were not with them during the hours in-between 
testing sessions  
 It was not feasible for our lab to measure magnesium levels delivered by application. 
Assumptions  
 All participants followed the pre-assessment guidelines.  
 All participants followed supplement application protocol during the testing period. 
 All participants refrained from all other forms of exercise during the testing period. 
Significance of Study 
 Magnesium is essential to many of the enzymatic processes associated with exercise. 
However, the uses of tMgCl2 as an aid to muscle performance have not been thoroughly 
researched.  By examining the effects of a tMgCl2 supplement on muscle soreness and force 
production compared to placebo, this study provided initial evidence to support a simple, 
affordable approach to reduce muscle damage following unaccustomed exercise. If proven 
effective this method of application could be used to further training efforts in the acute setting, 
by allowing athletes to recovery faster from intense training bouts and potentially allowing them 
7 
 
to accumulate greater training volumes and a greater cumulative effect in terms of chronic 



























CHAPTER II: Literature Review 
 
Eccentric Exercise and Exercise induced muscle damage (EIMD) 
 
Eccentric Mechanisms of Muscle Damage  
Exercise induced muscle damage (EIMD) can be categorized as the loss of muscle strength, 
and increase in muscle damage biomarkers and subsequent muscle soreness. (Nosaka et al., 
1996, Byrne et al., 2004, Tee et al., 2007). Previous literature has suggested that failure of 
excitation-contraction and sarcomere over-extension is the factor driving eccentrically induced 
EIMD (Morgan et al., 1990, Warren et al., 2001, Raastad T, et al., 2010). Calcium overload is 
believed to also be an enabler of EIMD (Armstrong et al., 1991) Excess calcium within cells 
impedes cellular respiration in the mitochondria (Cullen et al,1979), thus slowing ATP 
production and inhibiting the ability of the tissue to discard calcium (Wrogemann and Penna 
1976, Zulian et al., 2016). High calcium concentrations within the cell has been linked to 
structural and functional damaging of the mitochondria, cellular necrosis, z-disc degradation and 
energy shortage (Busch et al., 1972, Wrogemann and Penna 1976, Zulian et al., 2016).  
An eccentric contractions consist of the active lengthening of muscle under an external load 
(Douglas et al, 2016). Eccentric exercise has been used to examine EIMD because it is believed 
contraction-induced muscle tissue damage is more likely to happen in exercises using muscle 
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lengthening during activation (Armstrong et al., 1991, Proske et al., 2001, Warren et al., 2001).  
Eccentric contractions has also been believed to create higher local temperatures than concentric 
contractions (Daves and Barnes 1972). A rise in localized muscle temperature from exercise can 
possibly increase EIMD by breaking down of muscle fibers and connective tissues (Armstrong, 
1984) It has been shown that 3 sets of 30 maximal eccentric contractions of the knee extensors 
created a muscle damage response via significant increases in muscle damage biomarkers (Hody, 
2013). The proposed study utilized a randomized crossover placebo design with 6 sets of 12 
maximal eccentric contractions of knee extensors at 60o per/second utilizing a isokinetic 
dynamometer, which in theory would elicit a muscle damage response. 
Force Production  
Eccentric muscle contractions have been shown to cause greater fatigue and muscle soreness 
in comparison to isometric and concentric contractions (Jones et al., 1986). It has also been 
suggested that eccentric contractions cause the most soreness and damage at the tissue level 
(McCully and Faulkner, 1985).  Microscopic evidence has shown muscle damage via 
myofibrillar disorganization and Z-line disruption due to eccentric exercise (Friden et al., 1981, 
Lewis et al., 2013). There is a temporary reduction in isometric force generating capacity due to 
the tissue damage from eccentric exercise (Bryne et al. 2004). 24-48 hours after EIMD, peak 
force production deficits tend to occur as a result of eccentric exercise (Smith, 1991). Isometric 
strength has been accepted as a valid and reliable means of assessing muscle function following 
eccentric exercise (Warren et.al 1999). Taking into consideration the data presented above, the 
present study measured the maximum voluntary isometric contraction ability of quadriceps at 0, 




 Delayed Onset Muscle Soreness (DOMS) 
Delayed Onset Muscle Soreness (DOMS) is known as the development of pain, stiffness, and 
swelling of activated tissue from muscle micro trauma (Lewis et al., 2012) Previous literature has 
indicated that the swelling seen in DOMS is a result of EIMD and its consequent inflammatory 
response (Connolly et al., 2003). Input from mechanoreceptors may contribute to muscle 
soreness post eccentric exercise (Weekrakkoday et al 2001). It has been proposed that exercise-
induced release of chemical substances that elicit pain such may be the mechanism causing 
DOMS (Fock and Mense 1976). These same chemicals are thought to innervate the pressure 
receptors of afferent nerve endings sending sensations of pain upon touch (Hiss and Mense, 
1976). DOMs has been positively correlated with loss of force output and range of motion 
(Saxton et al., 1996, Prasarthwuth et al., 2006). Yet, there is evidence that DOMS has weak 
relationship with actual muscle damage (Rodenburg et al., 1993, Nosaka et al., 2002). DOMS 
appears to peak between 24 and 96 hours post exercise (Cheung et. Al, 2003). There has been 
work done with the visual analog scale (VAS) to effectively identify soreness in DOMS 
timelines (Lau et al., 2015, Kanda K et al., 2013). This proposed study evaluated muscle 
soreness using a VAS at 0, 24, 48 and 96 hours post eccentric exercise. 
Magnesium’s Role in Physiological Processes Relevant to Exercise  
Mg2+ in Cellular metabolism  
Magnesium at the cellular lever influences larger process such as membrane stabilization 
and metabolism of the muscle (Altura et al., 1996, Newhouse et al., 2000, Nielsen et al., 2006, 
Zhang 2017). In terms of metabolism, magnesium is pivotal to the allowance of enzymatic 
reactions. This function is critical to muscle recovery following exercise. Magnesium ions are 
also necessary for energy production within the cell. Processes such as glycolysis and beta 
oxidation rely on Magnesium enzymes (Swaminthan R, 2003, Pasternak et al, 2010). 
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Table 1 coveys the different enzymes, structures, and processes of energy metabolism that 
depend on Mg2+. 
Table 1: Physiological Functions of Magnesium (Swaminthan R, 2003) 
Mg Dependent Processes  Mechanism Affected or Aided  
Enzyme Function  Hexokinase 
Creatine Kinase 
Protein Kinase 
Direct Enzyme Activation Phosphofructokinase 
Creatine Kinase  
Adenylate Cyclase 
Na+, K+, ATPase 
Membrane Function Cell Lipid Adhesion  
Protein synthesis 
Calcium antagonist  Muscular Contraction/Relaxation 
Neurotransmitter release  
Action Potential Conduction  




Adenosine triphosphate is viewed as the fuel for life and nearly every reaction utilizing 
ATP demands the presence of magnesium (Touyz, 2004).The Mg-ATP complex (figure 1) is 
pivotal in metabolism and energy production (Maguire, 2006).  The Mg-ATP complex is 
essential in the catabolism of phosphotransferases, hydrolases, and ATPases during metabolic 
processes in the cell (Saris et al., 2000, Pasternak et al., 2010). While magnesium is well known 
to be essential to various metabolic and structural process, the specific nature of its role in tissue 
anabolism and catabolism is still uncertain. One of the more favored theories is that magnesium 
supports regeneration of tissue by aiding in cellular metabolism by assisting in the production of 




Figure 1: Magnesium is required for ATP to release stored energy to drive biological 
reactions within the cells (Rosanoff, 2015) 
Collectively, these studies suggest that the effects of Mg2+ on cell lipid stabilization and 
protein synthesis are benefits to maintaining membrane integrity, which is often compromised 
during different forms of resistance exercise. There has been evidence that showcased that the 
electrical effects of magnesium ions provide a stabilizing effect (Bara et. Al, 1990) Magnesium 
ions in the cell has been theorized to help stabilize the cell with its inhibition of calcium ion 
uptake (Kowaltowski et al., 1998, Iseri et al., 1984). It has also been suggested that magnesium 
helps to boost membrane function by binding to cellular phospholipids and organelle membranes 
(Golf et Al, 1998). Cellular lipid stabilization and protein synthesis are usually inhibited during 
resistance exercise, thus effecting the membrane integrity. This aforementioned evidence points 
to magnesium being a key factor in alleviating this issue. 
Magnesium’s role in muscle contraction  
During exercise, vasodilation of vessels allows for my oxygen to be delivered to work 
tissue by way. (Ishibashi et al., 1998, Duncker et al., 2008). This increased delivery of 
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oxygenated blood could allow for greater nutrient availability and repair post EIMD. There has 
been a research showing that a rise in the presences of magnesium ions prior to exercise results 
in increased blood flow allowing greater cross bridge formation (Haddy et. al, 1975). It has been 
theorized that since magnesium functions as an counteractant to calcium channels via blocking 
channels and decreasing intracellular calcium and consequent contractibility, which lowers 
peripheral vascular resistance and lowering the chance of overloading of calcium (Altura et al., 
1987). This inhibition of calcium channels by magnesium ions may promote more efficient 
contractions of working muscles by reducing the probability of calcium overload within the cell 
(Swaminathan R, 2003). It is also believed that magnesium ions enable efficient muscular 
contractions by allowing greater cross bride formation (Carvil P, Cronin J, 2010). All of these 
possible enhancements of muscular contraction has yet to be examined through the scope of local 
application of transdermal magnesium.  
Magnesium’s role in pain response  
Magnesium is voltage dependent blocker of N-methyl-D-aspartate (NMDA) receptor 
channels (Iseri and French, 1984, Ken and Kemp, 2005). NMDA receptor activation causes the 
spinal neurons to be more sensitive to inputs, causing a heightened pain stimulus through central 
sensitization (Bennett, 2000). There has been evidence that magnesium ions reduce 
inflammatory pain by minimizing NMDA receptor activity (Petrenko et al., 2003, Nechifor, 
2011). Post EIMD, there has been evidence that the muscle soreness experienced may be 
associated with the release of inflammatory mediators (Moyer and Wagner, 2011, Kanda et al., 
2013). Magnesium ions have been shown to minimize the release of these mediators and 
subsequently reducing the inflammatory response and consequent pain (Nechifor, 2011). 
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To our knowledge there has been no clinically controlled trials date investigating the effects of 
magnesium supplementation and DOMS from EIMD. However, there is a number of studies 
examining decreases in pain in clinical populations with oral supplementation. There has been 
evidence that oral supplementation of magnesium citrate in patients with coronary artery disease 
reduces exercise induced chest pain (Schester et al 2003). There has also been evidence that 1 
month of daily oral magnesium oxide supplementation (300 mg) decreased chronic low back 
pain with a neuropathic component (Yousef and Al-deeb, 2013). In terms of magnesium 
chloride, there has been evidence that transdermal application minimized chronic pain in patients 
with fibromyalgia (Engen et al., 2015). 
 Magnesium supplementation/concentration’s influence on performance   
There has been conflicting evidence on the effects of oral magnesium supplementation 
and exercise performance (Zhang 2017). It has been shown that there is a positive association 
with dietary magnesium intake and maximal isokinetic knee extension and flexion torque in 
“elite” level basketball and handball players (Santos et al. 2011) (See figure 2 & 3). In 
professional male volleyball players there was similar research done with 1 month of magnesium 
oxide oral supplementation, 350mg/day, and an increase in peak counter movement jump height. 
However there was no significant difference in maximum force production of the knee extensors 




   
 
The benefits of magnesium supplementation has also been seen in non-athletic 
populations. In untrained individuals, oral supplementation of magnesium oxide (8mg/kg) 
increased quadriceps torque in comparison to the placebo group (Brilla et al., 1992). The 
InCHIANTI study examined the effects of magnesium on muscle performance in an elderly 
population. This examination showcased a positive correlation between serum magnesium levels 
and maximal handgrip strength and knee extension torque (Dominguez et al., 2006). It is 
imperative to note that the InCHIANTI study did not utilize supplementation. However, this data 
does suggest that higher circulating levels of magnesium ions may be linked to having greater 
force production. The aforementioned research suggest that magnesium’s role in metabolism and 
structure at the cellular level may impact muscular contraction and subsequent force production. 
 Transdermal MgCl2 Treatment  
For years there have been anecdotal evidence for the use of mineral based theories, 
majority of which pointing to the potential health benefits. There has been conflicting evidence 
on the effectiveness of magnesium ion penetration via transdermal application. One study found 
Figure 2: Dietary Magnesium 
Intake Correlation w/ Isokinetic 
Strength (Santos et al. 2011). 
Figure 3: Dietary Magnesium 
Intake Correlation with Jump 
Performance (Santos et al. 2011) 
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that transdermal magnesium chloride supplementation penetrated the skin rapidly, and achieved 
significant permeation in 15 minutes (Chandrakanth et al 2016). However, there was no mention 
of the amount of magnesium that was able absorbed (Gröber 2017). After magnesium ions have 
crossed the stratum corneum, transmembrane proteins assist the transport of ions into the organ 
systems (Sahni et al. 2007). One study showcased that transdermal magnesium had greater 
effects than topical magnesium sulfate, which commonly used to treat pain (Bara et al., 1994). 
Transdermal magnesium chloride has also been favored in comparison to other topical agents, 
such as magnesium sulfate, because of its lower tissue toxicity (Durlach et al, 2005). 
To our knowledge, there had only been one study to date that examines the positive anti-
inflammatory effect of transdermal magnesium chloride supplementation in recreationally active 
individuals. In this study there was no correlation between the use of MagPro™ (Magnesium 
cream) and muscle flexibility or muscle endurance (Gulick et al 2012). We believed that due to 
the physiological processes that magnesium is involved in regards to contractibility and anti-
inflammation, it was best to examine the effects of transdermal magnesium on strength recovery 
and pain measures. It has been hypothesized that transdermal magnesium is absorbed quickly 
and thus more readily available for cellular use that oral supplementation. This in turn improving 
the ability of the muscle to function and recover from intense muscular contraction (Circus 
2007). A greater understanding of transdermal magnesium chloride was needed to justify claims 









CHAPTER III: Methodology 
 
Participants  
20 male subjects between the ages of 18-35 were recruited from a university in the 
southeast region of the United States. Due to the scarcity of previous literature regarding this 
particular application method in the desired population (Gulick et al, 2012), a sample size of 20 
was collected. In order to be included in this study, participants had to be recreationally active, 
30 or more minutes of exercise at least twice per week for a minimum of 2 months prior to 
enrollment. Each participant must also have had a previous history, within the past 3 months 
prior to enrollment, of resistance exercise. Each participant had to be free of any 
contraindications to exercise, acute knee injuries within the previous year, known magnesium 
deficiency, or utilizing magnesium supplementation and/or chronic pain medication in order to 
be enrolled. Females were excluded from this study due to there is a high degree of performance 
variability within women that appears to occur due to the menstrual cycle (Tenan et al 2015).  To 
minimize those confounding factors and potential variation in muscle soreness and isometric 




This study used a double blind, repeated measures crossover design. Participants were 
advised to abstain from any exercise or alcohol consumption 24-hours prior to arriving to the 
Exercise Oncology Lab for testing. Also, participants were instructed to not use an over the 
counter analgesics throughout the duration of the study.  
Testing Methods 
All testing and evaluations were performed in the Department of Exercise and Sport 
Science at the University of North Carolina in the Neuromuscular, Sports Medicine, and 
Exercise Oncology Laboratories located in Fetzer Hall.  
 
Body Composition Assessment   
 
Dual-energy X-Ray absorptiometry (DEXA; Hologic Discovery DXA System QDR 
Series, Hologic Breast and Skeletal Health Solutions, Marlborough, MA, USA) was used to 
estimate lean mass (LM), fat mass (FM), and bone mineral content to calculate total body 
composition. All scans were performed by a trained DEXA technician. Before each scan, the 
trained technician entered the required subject information including height (in), weight (lbs.), 
ethnicity, age, sex, and identification code. The participant was instructed to remove all metal 
jewelry and any other objects from their pockets, and then lie supine on the DEXA scanner. 
Once on the DEXA table, the technician adjusted the participant’s head, hips, shoulders, and 
limbs to center the participant within the DEXA’s measurement area. The participant was 
instructed to keep their hands pronated on the DEXA table next to their legs. The technician then 
inspected the positioning of the participant before wrapping the ankles to ensure the position was 
held throughout the scan. The participant was instructed to remain still in fixed position and 






  All blood draws occurred in the Exercise Oncology Laboratory and was conducted by an 
individual trained in phlebotomy. ~10mL of blood was obtained.  4mL of blood was collected in 
an EDTA tube and  complete blood counts with differential were determined in duplicate (XP-
300 Automated Hematology Analyzer, Sysmex America Incorporated, Lincolnshire, Illinois, 
USA), along with hemoglobin and hematocrit for determination of plasma volume shifts (Dill 
and Costill, 1973). A 6mL serum sample was allowed to clot for 30 minutes at room 
temperature, then centrifuged (1200 rpm X 10 min. at room temperature) and serum was 
obtained and aliquoted. These serum samples were stored at -80°C in a freezer (Thermo 
Scientific XBF40D-MD-Blast Freezer for Plasma, Waltham, MA, USA).   
Application of Condition- Placebo vs. Supplement   
Technicians used an analytic balance (Fisher Scientific XA Analytic Balance, Fisher 
Scientific, Hampton, New Hampshire, USA) to measure the mass (g) of both the balm and oil of 
the specified condition, and recorded this on the data sheet. Technicians then provided the 
condition to the participants post final isometric strength test on visit 2 and 6. Participants was 
instructed to apply their condition (placebo or supplement) by spraying 5 sprays from their bottle 
onto their quadriceps muscle of the tested leg. Once the participant felt that the spray had dried 
on their leg, they applied a quarter size dollop of the balm given to their quadriceps muscle on 
the tested leg. The participants were instructed to apply their condition after each visit to the lab, 
and during the evening and morning throughout the entire duration weeks of testing. After visit 5 
and visit 9, participants returned their balm and oil to the technician. The technician again used a 
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balance to measure the remaining mass of both the balm and oil of the specified condition, and 
recorded this on the data sheet.  
Gravity Correction  
Participants remained buckled in the dynamometer while the technician began the 
program “Research Toolkit”. The technician ensured the participant was comfortable before 
running the program. Once the participant was comfortable, the technician used the 
dynamometer to bring the participant’s knee to ~90 degrees flexion. A level was used to ensure 
that lower limb was vertical. The technician started the recording on the biopac (Biopac MP150, 
BIOPAC Systems Incorporated, Goleta, California, USA) and allowed the recording to run for 5 
seconds. The participant was then unbuckled from the dynamometer.  
Muscle Soreness: Visual Analogue Scale (VAS)   
A 100cm line in which participants indicated the level perceived of soreness between 0 – 
10. Each mark made on the analog line was examined to determine perceived muscle soreness 
for both the experimental and control supplements.  
Cycle Ergometer Warm-up  
Participants pedaled at light (25-50 watts) resistance for five minutes on the cycle 
ergometer prior to completing any exercise testing.  
Isometric Muscle Strength  
Participants were fitted to the isometric dynamometer (HUMAC Norm Testing and 
Rehabilitation System, Computer Sports Medicine Incorporated, Stoughton, MA, USA) and 
asked to perform single leg extension contractions at 50%, 75% and 90% of their perceived 
maximal effort with a knee angle of 90 degrees of flexion. Participants were given 1 minute to 
rest in between each warm-up effort. Participants then performed three, maximal isometric leg 
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extension efforts lasting 2-3 seconds, with 2 minutes of rest between each effort. The peak force 
from each trial was determined from the dynamometer and the highest value was used for 
calculations.  
Eccentric Muscle Damage Protocol  
To test the effects of the tMgCl2 on muscle recovery, it was decided to use an eccentric 
leg extensions. Eccentric training, as a model of unaccustomed exercise, has been shown to 
decrease force output and increase soreness. (Cheung et al 2003, Newham et al 1986: Proske et 
al 2001). Participants remained seated in the isometric dynamometer for 3 minutes after the 
isometric strength testing and prior to the eccentric protocol. Participants then performed 6 sets 
of 12 consecutive unilateral eccentric isokinetic knee extension contractions at a speed of 60 
degrees per second. Participants were asked to resist the downward movement of the 
dynamometer for all repetitions for a full range of motion, from ~0 degrees flexion through to 90 
degrees of flexion.  
Visit One 
  Participants were screened for participation in the study, which included a medical 
history questionnaire. If all inclusion criteria were met, participants were asked to sign the 
informed consent. Participants underwent a dual-energy x-ray absorptiometry scan to determine 
body and bone mineral composition. Then participants were taken to the neuromuscular lab to 
have the opportunity to practice and become familiar with all study procedures including knee 
extension strength testing, and eccentric leg extension protocol under submaximal conditions. As 
participants left the familiarization session, participants were reminded of the pre-exercise 




 Participants returned to the testing site 3-7 days after the familiarization session. Before 
performing exercise testing, participants filled out the baseline muscle soreness VAS and the 
research performed a blood draw. Following this, participants completed the cycle ergometer 
warm up. Participants were then fitted into the dynamometer before beginning the isometric 
strength testing portion of the visit. Post isometric strength testing and 3 minute rest period, 
participants completed the eccentric muscle damage protocol. Following this, participants were 
given another muscle soreness VAS, before completing another isometric strength test bout. 
Upon completion of the final strength test, participants were fitted for the gravity correction. 
After the gravity correction, participants were taken back to the Oncology Lab where they had 
another blood draw and were given their condition. Researchers showed the participant how to 
apply to the quadriceps. After application, they were reminded of both the application times 
before the next visit and the pre-assessment guidelines. 
Visit Three, Four, and Five  
Participants were asked to return to the lab for follow up muscle strength and soreness 
testing at 24h, 48h, and 96h after the eccentric exercise bout. Upon arrival to the lab, participants 
had their blood drawn and given a muscle soreness VAS. Participants were then taken to 
neuromuscular lab. In the lab they completed the cycle ergometer warm up before being fitted 
into the dynamometer for strength testing. Once fitted, the participants completed 1 bout of the 
isometric strength testing protocol before completing a gravity correction. After the gravity 
correction, the participant was unbuckled from the dynamometer and instructed to apply both 
their balm and oil to the tested leg. Before leaving, they were reminded of both the application 
times before the next visit and the pre-assessment guidelines. After the final strength testing 
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session (96 hr), participants were asked to return all supplements, to the researchers to estimate 
the amount of magnesium you received during the treatments.  
Washout period:  
2 weeks. During the washout period, participants were allowed and encouraged to resume 
their normal exercise routines. After the two-week washout period, participants returned to the 
laboratory and repeated the testing procedures using their opposite leg and the supplement 
condition.  
Visits 6-9  
Participants repeated testing (visits 2-5) from week 1 using the opposite supplementation 
condition. Participants used the opposite leg from week one to avoid a training or supplement 
effect from the first week of testing.  
Timing  
All participants were tested within ±1 hour of visit 2 for week 1 and visit 6 for week 2, as 
a means of controlling for variability in performance throughout the day. 
Sample Size  
To our knowledge, only one other study had investigated transdermal magnesium on 
muscle performance (Gulick et al, 2012) and the authors reported that in 18 healthy men and 
women, there was no effect on muscle endurance performance. Oral magnesium 
supplementation has been reported to enhance strength and Gulick and colleagues (2012) suggest 
that strength testing and also repeated applications of the product may produce larger effects. 
However, in the absence of scientific evidence to support this hypothesis, data by which to base 
statistical power calculations to estimate sample size are not available. As such, we are 
24 
 
approached this initial study as a pilot project in which we intended to improve upon existing 
knowledge by examining a different role for transdermal magnesium supplementation in a 
longitudinal manner, while restricting this initial study to males only. This initial project allowed 
for more appropriate power analyses to be conducted based on effect sixes calculated for this 
specific product in a more controlled population across a longer application period. 
Statistical Analysis 
Data will be analyzed using mixed-effects linear modeling (Jamovi 0.9.6.9) with repeated 
measures for the 2x5 crossover design. Magnesport and placebo condition effects was analyzed 
over time against perceived muscle soreness and maximal isometric force production. Potential 
covariates, such as leg dominance, were explored using descriptive statistics and the presence of 
an association with the dependent variables prior to being included in any statistical models. The 
potential order effect of the dominant vs. non-dominant leg were tested by comparing time x leg 
interaction of the dependent variable across time. The dominant leg was defined as the leg a 
participant would use to kick a ball for maximal distance. All statistical analyses were performed 











CHAPTER IV: Results 
 
Participants 
Participants were young, healthy, and recreationally active males with no history of lower 
extremity injuries within a year previous to testing (Table 1).  All participants had at least two 
months of prior experience with resistance training. All participants considered themselves to be 
at least moderately active and partook in various modes of both aerobic and resistance exercise. 
Of the 20 participants that were recruited, one was lost to follow up due to a mild allergic 
reaction to compounds within the product. 
Table 1. Participant characteristics (n=19).            
 Mean ± SD Range 
Age (y) 22 ± 2 19-24 
Height (cm) 177.4 ± 6.4 168.1-193 
Mass (kg) 83.7 ± 12.5 66.6-107 
Activity Levels (d/wk. ≥ moderate intensity) 4 ± 1 3-5 
Fat Mass (kg) 17.3 ± 7.1 8.5-28.5 
Lean Mass (kg) 64.0 ± 8.3 51.4-77.1 
% Body Fat 20.4 ± 5.9 11.9-35.1 
 
Whole Blood Markers and Hydration Status   
There was no difference in white blood cell, hemoglobin, or hematocrit throughout the 
duration of the trial, nor any difference between conditions. Thus indicating that participants had 
similar hydration levels during testing and appeared to be free of illness (Table 2).
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Table 2. Whole Blood Markers (n=14) 
WBC (x103/uL) Baseline 0H 24H 48H 96H 
tMgCl2 7.1 ± 1.9 6.8 ± 1.4 6.1 ± 1.4 6.3 ± 1.1 6.6 ± 1.7 
Placebo 6.4 ± 0.7 6.7 ± 1.4 6.3 ± 0.7 6.1 ± 1.0 6.8 ± 0.8 
LYM (x103/uL)  
tMgCl2 2.2 ± 0.5 2.0 ± 0.5 2.3 ± 0.6 2.3 ± 0.4 2.2 ± 0.6 
Placebo 2.1 ± 0.4 2.1 ± 0.6 2.3 ± 0.5 2.0 ± 0.5 2.1 ± 0.5 
MXD (x103/uL)  
tMgCl2 0.8 ± 0.2 0.7 ± 0.3 0.5 ± 0.2 0.6 ± 0.3 0.7 ± 0.3 




tMgCl2 4.1 ± 1.8 4.1 ± 1.4 3.3 ± 1.0 3.5 ± 1.0 3.7 ± 1.4 
Placebo 3.7 ± 0.6 3.9 ± 1.1 3.3 ± 0.7 3.5 ± 0.9 4.2 ± 1.2 
HGB (g/dL)      
tMgCl2 14.8 ± 0.7 14.8 ± 0.7 15 ± 1.2 14.8 ± 1.0 15.0 ± 0.7 
Placebo 14.9 ± 0.5 15.3 ± 2.0 14.8 ± 1.1 14.5 ± 1.0 14.7 ± 0.5 
HCT (%)      
tMgCl2 43.3 ± 2.0 43.2 ± 2.4 43.6 ± 2.3 43.1 ± 2.3 43.3 ± 2.1 
Placebo 43.3 ± 1.5 44.9 ± 6.0 43.1 ± 2.4 42.4 ± 2.1 43.0 ± 1.3 
PV (%)      
tMgCl2  0.5 ± 5.9 -1.7 ±8.9 1.9 ± 12.5 -1.6±10.1 
Placebo  7.8 ± 19.8 -4.4 ± 13.0 0.2 ± 6.8 2.9±5.8 
Mean ± SD 
* p<0.05 compared to baseline; ** p<0.01 compared to baseline 
 
tMgCl2 Application 
Participants appeared to be compliant with application guidelines for both conditions and 
there were no difference in the amount of product application between tMgCl2 and placebo 
(Table 3). The amount of MgCl2 delivered via transdermal oil was 743.7 ± 158.0 mg and 447.0 ± 
352.0 mg via transdermal balm for a total of 1,190.7 ± 510 mg, which was an average of 99.2 ± 




Table 3. Total Application Quantity for tMgCl2 Oil and Balm (n=19). 
 tMgCl2 Placebo P-Value 
tMgCl2 Oil (g) 
 
8.0 ± 1.7 8.4± 2.6 0.805 
tMgCl2 Balm  (g) 10.8 ± 8.5 11.2 ± 7.1 0.700 
Mean ± SD 
 
Isometric Knee Extensor Muscle Strength  
Immediately following eccentric exercise muscle contractions (0H), knee extensor 
isometric raw torque decreased by ~12% (-36.5 N*m, 95%CI [-6.3, 39.3], p<0.001) relative to 
baseline (Table 4). Torque tended to be lower than baseline at 24H (-10%, -15.9 N*m, 95%CI [-
31.9, 0.2], p=0.055), was similar to baseline at 48H (1.3 N*m, 95%CI [-14.8, 17.4], p=0.877) 
before increasing by 16% at 96H (34.98 N*m, 95%CI [18.6, 51.3], p<0.001). There was no 
group x time interaction or condition main effect. 
Table 4. Absolute Isometric Force Production of the Knee Extensors (n=19). 
 
 Visual inspection of the raw torque between placebo and tMgCl2 indicated a difference at 
baseline (Table 4). As such, leg dominance was added to the analysis and the full model was 
presented below (Table 5). The time x condition interaction was not significant (p=0.886), but 
the condition x leg dominance was significant (p=0.045). The full model had a slightly larger 
conditional R2 and lower AIC, indicating a better model for these data. 
Condition Baseline 0H 24H 48H 96H  
tMgCl2 (N*m) 
 
271 ± 83 239 ± 72 261 ± 68 278 ± 85 314 ± 90  
Placebo (N*m) 287 ± 73 246 ± 66 265 ± 73 274 ± 76 297 ± 85  
Total (N*m) 279 ± 78 243 ± 68** 263 ± 70 276 ± 80 305 ± 87**  
 F ratio Num df Den df P value AIC Cond. 
R2 
Time 20 4 169 <0.001 1977 0.7961 
Condition 2.0 1 169 0.229   
Time x Condition       0.3 4 169 0.888   
Mean ± SD 
* p<0.05 compared to baseline; ** p<0.01 compared to baseline 
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Table 5. Full Model for Maximal Knee Extensor Isometric Force Production Adjusted for Leg 
Dominance (n=19). 
  
There was a 12% decrease in torque when adjusting for leg dominance the 0H (-36.5, 
95%CI [-52.1, -20.8], p<0.001) relative to baseline. At 24H, torque decreased by 5% in 
comparison to baseline (-15.9, 95%CI [-31.5, -0.2], p=0.049); but was similar to baseline at 48H 
(1.3, 95%CI [-14.4, 16.9], p=0.873) before a 12% increase by 96H (34.9, 95%CI [19.1, 50.8], 
p<0.001).  
Because this was a pilot study and to maximize degrees of freedom, any non-significant 
group x condition interaction were removed and the reduced model was presented (Table 6).  In 
the reduced model, there was a significant difference seen at the 0H (-36.5, 95%CI [-52.1,-20.8], 
p<0.001), 24H (-15.9, 95%CI [-31.5,-0.2], p =0.049), and 96H (35.0, 95%CI [19.1, 50.9], 
p<0.001) continued. 
The marginal means between the full and reduced model did not greatly vary, which 
could be seen in the similar trend of the data between models. In comparison to the raw and full 
model, there was no difference in conditional R2.  
 
Condition Baseline 0H 24H 48H 96H  
tMgCl2 (N*m) 275  ± 17 243  ± 17 266  ± 17 382  ± 17 317  ± 18  
Placebo (N*m) 283  ± 17 242  ± 17 260  ± 17 278  ± 17 310  ± 18  
Total (N*m) 279  ± 16 242  ± 16** 263  ± 16* 280  ± 16 314  ± 16**  
 F ratio Num df Den df P value AIC Cond
. R2 
Time 20.6 4 168 <0.001 1973 0.804 
Condition 0.1 1 168 0.740   
Leg Dominance 8.0 1 168 0.005   
Time x Condition       0.3 4 168 0.886   
Marginal Mean ± SE 
* p<0.05 compared to baseline; ** p<0.01 compared to baseline 
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Table 6.  Reduced Model for Maximal Knee Extensor Isometric Force Production Adjusted for Leg 
Dominance (n=19). 
       
         To confirm the influence of leg dominance on torque, peak torque values were normalized 
to baseline within subjects. The interaction of time x condition remained non-significant 
(p=0.375), confirming the full and reduced torque models. As expected, leg dominance was no 
longer a significant factor in the model (p=0.789). There was a trend for an effect of condition 
(2.7%, 95% CI [-0.1, 5.5], p= 0.058). There were significant decreases in relative torque at 0H (-
12.8%, 95% CI [-17.2, -8.4], p<0.001) and 24H (-4.6%, 95% CI [-8.9, -0.2], p= 0.043); but no 
difference at 48H, as participants had returned to baseline output (-0.3, 95% CI [-4.7, 4.1], p= 
0.888). At 96H, relative torque exceed baseline by nearly 4% (Table 6), but was not statistically 
significant (3.4, 95% CI [-0.9, 7.8], p= 0.125). 
Table 7. Normalized Model for Maximal Knee Extensor Isometric Force Production (n=19) 
Condition Baseline 0H 24H 48H 96H  
tMgCl2 (N*m) 275 ± 16 243 ± 16 266 ± 16 282 ± 16 317 ± 16  
Placebo (N*m) 283 ± 16 242 ± 16 260 ± 16 278 ± 16 310 ± 16  
Total (N*m) 279 ± 16 242 ± 16** 263 ± 16* 280 ± 16 314 ± 16**  
 F ratio Num df Den df P value AIC Cond. 
R2 
Time 20.9 4 172 <0.001 2004 0.807 
Condition 0.1 1 172 0.742   
Leg Dominance       8.2 1 172 0.005   
Marginal Mean ± SE 
* p<0.05 compared to baseline; ** p<0.01 compared to baseline 
Condition Baseline 0H 24H 48H 96H  
tMgCl2 (N*m) 100 ± 2 89 ± 2 98 ± 2 103 ± 2 103 ± 2  
Placebo (N*m) 100 ± 2 86 ± 2 93 ± 2 96 ± 2 104 ± 2  
Total (N*m) 100 ± 2 87 ± 2** 95 ± 2* 100 ± 2 103 ± 2  
 F ratio Num df Den df P value AIC Cond. R2 
Time 15.7 4 175 <0.001 1488 0.215 
Condition 3.6 1 175 0.058   
Marginal Mean ± SE 





Following eccentric exercise, muscle soreness increased at 0H (26.6mm, 95% CI [20.1, 
33.1], p<0.001) that remained elevated above baseline at 24H (22.1, 95% CI [15.6, 28.6], p<0.001) 
and 48H time points (20.2, 95% CI [13.7, 26.7], p<.001). By the 96H time point, participants had 
returned to baseline soreness (3.3, 95% CI [-5.5, 2.7], p = 0.510). tMgCl2 slightly attenuated 
perceived degree of soreness (17.6, 95%CI [11.7, 23.6]) in comparison to placebo (19.0, 95%CI 
[13.0, 25.0]); however, this difference was not statistically significant (p = 0.510) (Figure 1).  




Condition Baseline 0H 24H 48H 96H  
tMgCl2 (mm) 3.4 ± 4.2 29.1 ± 4.2 25.7 ± 4.2 23.0 ± 4.2 6.8 ± 4.2  
Placebo (mm) 4.3 ± 4.2 31.8 ± 4.2 26.3± 4.2 25.1 ± 4.2 7.6± 4.2  
Total (mm) 3.9± 3.4 30.5 ± 3.4** 26.0 ± 3.4** 24.0 ± 3.4** 7.2 ± 3.4  
 F ratio Num df Den df P value AIC Marg. R2 
Time 25.3 4 153 <0.001 1446 0.270 
Condition 0.4 1 153 0.510   
Time x Condition 0.0 4 153 0.997   
Marginal Mean ± SE 
* p<0.05 compared to baseline; ** p<0.01 compared to baseline 
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CHAPTER V: Discussion 
 
Athletes commonly use supplementation for a competitive edge (Knapik 2016), yet the 
world of supplements is an ever-expanding market with little scientific backing to many of the 
products on shelves (Peeling et al. 2018). Magnesium (Mg), a mineral linked to more 300 
enzymatic processes, may be linked to increased muscle force and could be used to improve 
recovery following unaccustomed exercise. However, there has been minimal work on the 
effects of a transdermal application of magnesium chloride (tMgCl2) supplement and muscle 
performance. The purpose of this double-blind crossover study was to investigate the effects of a 
transdermal magnesium supplement on muscle force production recovery and perceived muscle 
soreness. Our major findings was that the use of tMgCl2 appears to have minimal effect on 
recovery of knee extensor muscle torque following eccentric exercise, nor did it reduce the onset 
of muscle soreness in young, recreationally active men. These findings contradict our hypotheses 
that the use of this supplement would increase muscle force recovery and minimize perceived 
muscle soreness in comparison to a placebo. Under the current application protocol, this study 
suggests that tMgCl2 has little apparent benefit, with the relatively small dosage being a possible 
reason for the lack of change.   
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Limitations and Strengths  
To contextualize this study, the limitations and strengths of the study are described 
initially. We used recreationally active young males and these results and the application 
protocols used may not be generalizable to other populations. We were not able to determine if 
tMgCl2 altered circulating levels. As only ~1% of the body’s Mg is detectable in extracellular 
stores (Dean 2017, Jahnen-Dechent 2012 ), extensive tests must be used to assess total body Mg 
levels but were beyond the scope of this study. Besides subjective measures, we were not able to 
control dietary intake throughout the course of the study nor verify (other than verbal 
confirmation) that the participants were not active during the weeks of testing. We assessed the 
different conditions on opposite legs, which led to a difference in baseline strengths most likely 
due to leg dominance. While leg dominance was used as a covariate to adjust for this difference, 
the use of different limbs was deemed necessary as delayed onset muscle soreness and peak 
torque are both attenuated following even a single session (McHugh 2003, Nikolaidis et al. 
2007). Being a pilot study, it now seems we were underpowered to discover this interaction 
effect. While we saw a trend, more subjects would be needed for these observations to be 
statistically significant. 
Strengths of this study include the design, being a double-blind, randomized control trial 
performed in healthy men with previous resistance training experience. The use of a 
familiarization session and previous lifting experience likely permits a greater and more reliable 
effort to unaccustomed exercise and to control for learning effects but may have affected the 
torque and soreness responses. An estimate of total Mg applied to the muscles was also 
determined, which has not previously been reported (Gulick 2012).  
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Comparisons with Previous Literature  
Muscle Force Recovery 
We found that the use of tMgCl2 provided no additional benefit in increasing muscle 
force recovery. In all three of the statistical models run (raw, full, reduced), the response 
following eccentric exercise was similar. There was a significant decrease in force production at 
the 0H and 24H time point that was gone by 48H. By 96H, a super compensation phase is 
apparent, as torque values exceeded baseline.  
The reason for employing multiple models is that distinct difference between conditions 
for the baseline torque were observed. While there are several potential explanations, leg 
dominance seemed to be most likely. To fully test the effects of tMgCl2 on recovery and 
soreness, it was necessary to use different legs for each condition. While rapid eccentric knee 
extensions were likely to be an unaccustomed stimulus, a second exposure to the same limb 
potentially confounds the results as soreness and muscle damage are attenuated following 
exposure (Clarkson 1992, Nikolaidis et al. 2007). These differences were better managed 
through normalization to baseline or including leg dominance as a covariate. In both the full and 
reduced models, leg dominance was a significant factor and when the data were normalized to 
baseline, the confounding effect of leg dominance was removed, as expected. Interestingly when 
compared to placebo, tMgCl2 had a 4% increase in normalized peak torque by the 96H. While 
not statistically significant, an increase in force output of this magnitude in response to a single 
exercise session has potential to translate into improved athletic performance if these differences 
were sustained across multiple training sessions. 
The eccentric exercise protocol used had previously been shown to elicit a 20% decrease 
in force and increased soreness (Hicks et.al 2016). Interestingly, the current study reports only a 
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12%, which may be due to a number of factors. The previously studied population was similar in 
age and being recreationally active, but they did not have a resistance training background 
(Hicks et. al 2016). Therefore, our population may have been more prepared to handle the rapid, 
lengthening contractions due to previous exposure to eccentric loading conditions during 
resistance training, thus producing an attenuated response. Also it is noteworthy to mention that 
while we attempted to account for leg dominance by utilizing a crossover design, this pilot study 
having a small sample size did not allow us to tease out the variability of this covariate. Thus 
when we examined the 96H time point for the full and reduced model we still saw a significant 
difference in comparison to baseline, but once we normalized the values the 96H time point was 
no longer statistically significant. This is not to say we did not see an increase in the marginal 
mean for tMgCl2. Which eludes to there may be a slight increase in force production recovery at 
that time point, but we were too underpowered to detect it. 
 tMgCl2 is understudied within the context of muscle performance, with only one previous 
study to our knowledge looking at a similar supplement (Gulick 2012) examined flexibility and 
endurance. However, oral supplementation and dietary intake has been investigated more 
thoroughly in regards to force production. Santos 2012 showcased the relationship between 
dietary magnesium intake maximal isokinetic knee extension and flexion torque in “elite” level 
basketball and handball players. Here they found that there was a linear relationship between 
dietary intake and their primary outcomes. However, it should be noted that there range for 
intake was from 100-500 mg. In comparison to our investigation, where we were only able to 
deliver 99 mg per application. In contrast, Setaro et al. 2014 found that in professional male 
volleyball players a 350mg/day dose for a month was not enough to elicit a significant response 
in knee extensor force production. There has also been positive effects seen in force production 
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with oral magnesium supplementation, but in untrained and/or older individuals (Brilla et al. 
1992, Dominguez et al. 2006). The trend stays the same that higher Mg intake is linked to higher 
force outputs. Our investigation enabled the perspective of a transdermal approach to increasing 
force production with Mg supplementation.  
Perceived Muscle Soreness 
There is limited work on perceived muscle soreness and the use of magnesium 
supplementation, with this study being the first to our knowledge to examine this link. While Mg 
is known to be beneficial in alleviating pain in clinical populations (Schester et al. 2003, Yousef 
and Al-deeb 2013, Engen et al. 2015), it has not been investigated in a healthy and recreationally 
active populations. tMgCl2 was shown to be not effective in minimizing perceived muscle 
soreness in our chosen population. As stated earlier, this could be due to the population’s 
acclimatization to the severity of the protocol from their resistance training background. 
According to Hawker et al. 2011, the VAS values reported by our participants only place them in 
the category experiencing “mild pain” at their peak soreness. Coupled with the attenuated torque 
reductions, the eccentric load may have been insufficient for the population used and could have 
minimized the effects of tMgCl2.  However, the effect of soreness across time was consistent 
between our inquiry and previous literature. Hicks et al. 2016 showing a significant effect of 
time but no difference between groups (male and female). While we utilized a similar protocol, 
Hicks et al. 2016 reported the most significant soreness at the 24H time point, but we saw our 
most significant increase at 0H, which was unexpected. There was a slightly attenuated response 
between tMgCl2 and placebo, but it was not statistically significant.  
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Implications and Future Studies 
Supplementation is a known aid for competitive performance (Peeling et al. 2018). There 
are numerous supplements available to the general public, and it is estimated to continue to grow 
exponentially (Gabriels 2013). As such, it is important that scientific evidence is available to 
investigate the claims being made by supplement manufacturers. Mg is necessary for various 
enzymatic process (Jahnen-Dechent et al. 2012) and has been thoroughly researched in terms of 
performance and oral intake and oral supplementation. It was hypothesized that transdermal 
supplementation would follow suit of its oral counterpart and increasing the amount of Mg 
available would enhance our desired outcomes of muscle force recovery and perceived muscle 
soreness by applying the Mg directly to the muscle. However, our results were statistically non-
significant for conditions. While our findings were not what we hypothesized, we were able to 
provide a deeper knowledge to the anecdotal claims of tMgCl2. While not statistically 
significant, we did see a slight favoring of tMgCl2. These findings suggest that there is potential 
benefit in the micro-cycle of training, which could possibly lead to greater gains in the 
mesocycle and macrocycle. While we did not find a significant effect of utilizing ~100 mg per 
application of tMgCl2, it may be necessary to examine higher dosages in the future. As stated 
earlier, while there has been research that has examined the effects of dietary or magnesium 
intake or oral supplementation on performance, there is a paucity of research on the effects of 
transdermal application on performance such that firm conclusions are not possible at this stage. 
Under the current conditions, tMgCl2 does not appear to be as beneficial as previously 





 In conclusion, many ergogenic aids aimed at increasing performance are supported by no 
more than anecdotal claims. Based on previous literature showcasing the positive effects of 
dietary intake and oral Mg supplementation on force production, soreness and pain; we 
hypothesized that tMgCl2 would enhance force production recovery and minimize perceived 
muscle soreness. Our investigation indicates no effect of tMgCl2 for both perceived muscle 
soreness and muscle force recovery. The eccentric load used may have been insufficient, as 
evidenced by the attenuated torque loss and soreness relative to previous work (Hicks 2016), and 
thus may have minimized any benefits of tMgCl2. Future investigations should consider using 
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